IP Library › Granted Patent US 12,247,216
Granted Patent B2
US 12,247,216 · App. 17/610,485 · Granted Mar 11, 2025

Pluripotent cell aggregates and use thereof

Inventors: Neta Lavon (Ness Ziona, IL); Didier Toubia (Raanana, IL); Anna Bodanovsky (Tel Aviv, IL)
Assignee: ALEPH FARMS LTD.
C12N5/0606C12N2501/115C12N2501/415C12N2510/00C12N2511/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,216
App. No.
17/610,485
Granted
Mar 11, 2025
Kind
B2
Abstract

The present invention relates to compositions and methods for mass production of pluripotent stem cells derived from non-human-animal, particularly in a form of aggregates suitable for a variety of uses, particularly to mass production of aggregates of bovine-derived pluripotent stem cells for use in cell grown meat cultures and in production of cell based meat products.

Claims (24)

1. A method of producing aggregates of non-genetically modified non-human-animal-derived pluripotent stem cells (PSCs) comprising the steps of:

a. seeding at least one PSC in an expansion medium, the expansion medium is a serum-free liquid medium comprising a combination of the growth factor bFGF and at least one of (i) at least one additional growth factor and (ii) at least one small molecule selected from the group consisting of an inhibitor of the Wnt-β-catenin signaling pathway, CHIR 99021 (C22H18Cl2N8), PD 0325901 (C16H14F3IN2O4), and A 83-01 (C25H19N5S), to form a seeding suspension culture; and

b. growing the suspension culture under conditions enabling aggregate formation and aggregate expansion, thereby forming homogenous aggregates of the PSCs.

2. The method of claim 1 , wherein step (b) of growing the suspension culture comprises performing at least once the steps of (i) disaggregating the formed homogenous aggregates into smaller aggregates and/or single cells and (ii) re-aggregating the smaller aggregates and/or single cells to re-form homogenous aggregates.

3. The method of claim 1 , wherein the method is performed in a closed system.

4. The method of claim 1 , wherein the expansion medium comprises a combination comprising bFGF and at least one small molecule.

5. The method of claim 1 , wherein the at least one additional growth factor is a protein of the transforming growth factor beta (TGF-β) superfamily.

6. The method of claim 1 , wherein the expansion medium comprises a combination comprising bFGF and at least one additional growth factor, wherein the at least one additional growth factor is a protein of the TGF-β superfamily selected from the group consisting of TGF-β-1, TGFβ-3, and Activin-A.

7. The method of claim 1 , wherein step (a) of seeding the at least one PSC further comprises encapsulating the at least one PSC within a particle and seeding a plurality of the particles within the expansion medium.

8. The method of claim 1 , wherein the suspension culture is grown at a temperature which is the body temperature of the non-human-animal species from which the cells are derived.

9. The method of claim 1 , wherein the PSC aggregates formed have an average diameter of from about 50 μm to about 500 μm.

10. The method of claim 1 , wherein the non-human-animal is bovine, and wherein the bovine PSCs are embryonic stem cells produced by a method comprising the steps of:

i. obtaining at least one bovine pre-embryo;

ii. culturing the at least one pre-embryo to reach blastocyst or enhanced blastocyst stage;

iii. obtaining at least one cell from the blastocyst; and

iv. culturing the at least one cell in a culture medium comprising a combination of the growth factor bFGF, and at least one of (i) at least one additional growth factor and (ii) at least one small molecule selected from the group consisting of an inhibitor of the Wnt-β-catenin signaling pathway, CHIR 99021 (C22H18Cl2N8), PD 0325901 (C16H14F3IN2O4), and A 83-01 (C25H19N5S), to obtain a plurality of bovine-derived embryonic stem cells.

11. The method of claim 1 , wherein the non-human-animal PSCs are induced pluripotent stem cells (iPSCs) produced by a method comprising introducing into at least one non-human-animal-derived cell a combination of:

a. at least one reprogramming mRNA encoding reprogramming factor; and

b. at least one double-stranded microRNA; or

C. at least one inhibitor of at least one microRNA endogenous to the non-human-animal-derived cell;

thereby producing at least one iPSC.

12. The method of claim 11 , wherein the method further comprises introducing into the at least one non-human-animal-derived cell at least one immune evasion mRNA.

13. The method of claim 11 , wherein introducing the at least one reprogramming mRNA, and/or the at least one immune evasion mRNA and/or the at least one double-stranded microRNA and/or the at least one miRNA inhibitor is performed in a serum-free liquid expansion medium, and wherein the at least one mRNA is not integrated into the genome of the cell.

14. The method of claim 1 , wherein the homogenous aggregates comprise at least 70% of cells expressing at least one pluripotency marker.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2021
From: LAVON, NETA; TOUBIA, DIDIER; BODANOVSKY, ANNA
To: ALEPH FARMS LTD.
Reel/Frame 058084/0515 →
Continuity (2)
Provisional Application 62847345 · May 14, 2019
Related Publication 20220220439A1 · Jul 14, 2022
References Cited (92)
US 6835390B1 · Vein · 2004 [cited by applicant]
US 9752122B2 · Marga · 2017 [cited by applicant]
US 9834749B2 · Amit · 2017 [cited by applicant]
US 9944894B2 · Davis · 2018 [cited by applicant]
US 10669524B2 · Forgacs · 2020 [cited by applicant]
US 10669525B2 · Yokoyama · 2020 [cited by applicant]
US 20140093618A1 · Forgacs · 2014 [cited by applicant]
US 20180371036A1 · Yamanaka · 2018 [cited by applicant]
US 20190078057A1 · Jaenisch · 2019 [cited by applicant]
AU 2014200783B2 · 2016 [cited by applicant]
AU 2017225083B2 · 2019 [cited by applicant]
CN 105555949A · 2016 [cited by applicant]
GB 2617629A · 2023 [cited by applicant]
JP 2014521336A · 2014 [cited by applicant]
JP 2019162054A · 2019 [cited by applicant]
WO 9003432A1 · 1990 [cited by applicant]
WO 9931223A1 · 1999 [cited by applicant]
WO 2006041429A2 · 2006 [cited by applicant]
WO 2007069666A1 · 2007 [cited by applicant]
WO 2008015682A2 · 2008 [cited by applicant]
WO 2008124133A1 · 2008 [cited by applicant]
WO 2008136733A1 · 2008 [cited by applicant]
WO 2009032194A1 · 2009 [cited by applicant]
WO 2009075119A1 · 2009 [cited by applicant]
WO 2009133971A1 · 2009 [cited by applicant]
WO 2009152529A2 · 2009 [cited by applicant]
WO 2009157593A1 · 2009 [cited by applicant]
WO 2010013845A1 · 2010 [cited by applicant]
WO 2010017562A2 · 2010 [cited by applicant]
WO 2010124091A1 · 2010 [cited by applicant]
WO 2010124290A2 · 2010 [cited by applicant]
WO 2010137746A1 · 2010 [cited by applicant]
WO 2011016588A1 · 2011 [cited by applicant]
WO 2011158960A1 · 2011 [cited by applicant]
WO 2012036299A1 · 2012 [cited by applicant]
WO 2012060473A1 · 2012 [cited by applicant]
WO 2012074117A1 · 2012 [cited by applicant]
WO 2012087965A2 · 2012 [cited by applicant]
WO 2013014929A1 · 2013 [cited by applicant]
WO 2013159103A1 · 2013 [cited by applicant]
WO 2013173248A2 · 2013 [cited by applicant]
WO 2013176233A1 · 2013 [cited by applicant]
WO 2013188679A1 · 2013 [cited by applicant]
WO 2014039938A1 · 2014 [cited by applicant]
WO 2014189144A1 · 2014 [cited by applicant]
WO 2014200030A1 · 2014 [cited by applicant]
WO 2014200114A1 · 2014 [cited by applicant]
WO 2015056804A1 · 2015 [cited by applicant]
WO 2015066377A1 · 2015 [cited by applicant]
WO 2016210313A1 · 2016 [cited by applicant]
WO 2017124100A1 · 2017 [cited by applicant]
WO 2018011805A2 · 2018 [cited by applicant]
WO 2018015954A1 · 2018 [cited by applicant]
WO 2019016795A1 · 2019 [cited by applicant]
WO 2019140260A1 · 2019 [cited by applicant]
WO 2021207293A1 · 2021 [cited by applicant]
WO 2022104378A1 · 2022 [cited by applicant]
WO 2023003470A1 · 2023 [cited by applicant]
WO 2023003471A1 · 2023 [cited by applicant]
Lewandowski et at., “Techniques for the induction of human pluripotent stem cell differentiation towards cardiomyocytes,” J Tissue Eng Regen Med 11:1658-1674, 2017. [cited by examiner]
Anokye-Danso et al., (2011) Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8(4): 376-388. [cited by applicant]
Beeravolu et al., (2017) Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta. J Vis Exp 122: e55224; 13 pages. [cited by applicant]
Bogliotti et al., (2018) Efficient derivation of stable primed pluripotent embryonic stem cells from bovine blastocysts. Proc Natl Acad Sci U S A 115(9): 2090-2095. [cited by applicant]
Boroviak and Nichols (2017) Primate embryogenesis predicts the hallmarks of human naïve pluripotency. Development 144(2): 175-186. [cited by applicant]
Cao et al., (2012) Characterization of bovine induced pluripotent stem cells by lentiviral transduction of reprogramming factor fusion proteins. Int J Biol Sci 8(4): 498-511. [cited by applicant]
Castro Neto et al., (2005) Improvement in embryo recovery using double uterine flushing. Theriogenology 63(5): 1249-1255. [cited by applicant]
Dakhore et al., (2018) Human Pluripotent Stem Cell Culture: Current Status, Challenges, and Advancement. Stem Cells Int 2018: 7396905. [cited by applicant]
Davis et al., (2018) Automated Closed-System Expansion of Pluripotent Stem Cell Aggregates in a Rocking-Motion Bioreactor. SLAS Technol 23(4): 364-373. [cited by applicant]
Diecke et al., (2015) Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci Rep 5: 8081; 9 pages. [cited by applicant]
Ezashi et al., (2012) Induced pluripotent stem cells from pigs and other ungulate species: an alternative to embryonic stem cells? Reprod Domest Anim 47 Suppl 4: 92-97. [cited by applicant]
Ezashi et al., (2016) Pluripotent Stem Cells from Domesticated Mammals. Annu Rev Anim Biosci 4: 223-253. [cited by applicant]
Han et al., (2011) Generation of induced pluripotent stem cells from bovine embryonic fibroblast cells. Cell Res 21(10): 1509-1512. [cited by applicant]
Huang et al., (2011) A virus-free poly-promoter vector induces pluripotency in quiescent bovine cells under chemically defined conditions of dual kinase inhibition. PLoS One 6(9): e24501; 14 pages. [cited by applicant]
Kahn (2014) Can we safely target the WNT pathway? Nat Rev Drug Discov 13(7): 513-532. [cited by applicant]
Kim et al., (2013) Modulation of β-catenin function maintains mouse epiblast stem cell and human embryonic stem cell self-renewal. Nat Commun 4: 2403; 11 pages. [cited by applicant]
Lei and Schaffer (2013) A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc Natl Acad Sci U S A 110(52): E5039-E5048. [cited by applicant]
Li et al., (2018) A fully defined static suspension culture system for large-scale human embryonic stem cell production. Cell Death Dis 9(9): 892; 9 pages. [cited by applicant]
Li et al., (2018) Scalable and physiologically relevant microenvironments for human pluripotent stem cell expansion and differentiation. Biofabrication 10(2): 025006; 16 pages. [cited by applicant]
Ogorevc et al., (2016) Cellular reprogramming in farm animals: an overview of iPSC generation in the mammalian farm animal species. J Anim Sci Biotechnol 7: 10; 9 pages. [cited by applicant]
Poleganov et al., (2015) Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Hum Gene Ther 26(11): 751-766. [cited by applicant]
Roberts et al., (2015) Livestock models for exploiting the promise of pluripotent stem cells. ILAR J ;56(1): 74-82. [cited by applicant]
Song et al., (2012) Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res 27(11): 2344-2358. [cited by applicant]
Takahashi and Yamanaka (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4): 663-676. [cited by applicant]
Takahashi et al., (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5): 861-872. [cited by applicant]
Talluri et al., (2015) Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming. Cell Reprogram 17(2): 131-140. [cited by applicant]
Watanabe et al., (2005) Directed differentiation of telencephalic precursors from embryonic stem cells. Nat Neurosci 8 (3): 288-296. [cited by applicant]
Yoshida et al., (2009) Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 5(3): 237-241. [cited by applicant]
Yu et al., (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858): 1917-1920. [cited by applicant]
Zeng et al., (2018) MicroRNAs: Important Regulators of Induced Pluripotent Stem Cell Generation and Differentiation. Stem Cell Rev Rep 14(1): 71-81. [cited by applicant]
Zur Nieden et al., (2007) Embryonic stem cells remain highly pluripotent following long term expansion as aggregates in suspension bioreactors. J Biotechnol 129(3): 421-432. [cited by applicant]
“Epigenetics and Precision Medicine”, (2017) Zhu Jingde, pp. 413-414, Shanghai Jiao Tong University Press. With machine translation. [cited by applicant]
Wu et al., (2015) An alternative pluripotent state confers interspecies chimaeric competency. Nature 521(7552): 316-321. [cited by applicant]